<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1481">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895400</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-2013-0165</org_study_id>
    <secondary_id>20130055275</secondary_id>
    <nct_id>NCT01895400</nct_id>
  </id_info>
  <brief_title>Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy</brief_title>
  <acronym>REREV</acronym>
  <official_title>A Single-center, Prospective, Randomized, Parallel Group, Placebo-controlled Exploratory Study on the Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jong Woo Chung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Renexin is effective in the treatment of
      vestibular symptoms in patients with recurrent vestibulopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Study design

             -  Among patients who visitied for recurrent vertigo more than 3 months, patients
                will be included after ruling out other peripheral vertigo through history taking,
                physical examination, Dix-Hallpike test, head-thrust test.

             -  Included patients will go through permission, laboratory tests (CBC, chemical
                battery, coagulation battery, urine HCG (only women of childbearing age),
                posturography. During patients selection period for inclusion(2 weeks), taking
                medication for vertigo is prohibited.

             -  Included patients will be randomized to Treatment group (Renexin) and Placebo
                group.

             -  All patients before treatment will do dizziness handicap inventory(DHI), visual
                analogue scale (VAS) for vertigo, questionnaire for quality of life (SF36).

             -  After 4 weeks(+-~ 3 days) of drug administration, DHI, VAS for vertigo, SF36 will
                be done for drug compliance and side effects.

             -  After 8 weeks(+-~ 3 days) of drug administration, posturography, DHI, VAS for
                vertigo, SF36 will be done for drug compliance and side effects.

             -  For control of severe vertigo during drug administration, Valium 2mg can be used
                as a salvage treatment, and number of valium administration will be checked at
                every visit.

        2. Statistical analysis

             -  As a statistical analysis, paired T-test will be used to compare equilibrium
                score, DHI, VAS, SF-36. When p-value is &lt;0.05, it will be considered as
                significant difference.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>equilibrium score of dynamic posturography</measure>
    <time_frame>after 8 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>compared with pretreatment equilibrium score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>dizziness handicap inventory</measure>
    <time_frame>at 4 weeks, 8 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>compared with pretreatment DHI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual analogue scale (VAS) of vertigo</measure>
    <time_frame>at 4 weeks, 8 weeks after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>compared with pretreatment VAS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire for Quality of life (SF36)</measure>
    <time_frame>at 4 weeks, 8 weeks after treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>compared with pretreatment SF36 score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Recurrent Vestibulopathy</condition>
  <arm_group>
    <arm_group_label>Renexin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Renexin 1T bid for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1T bid for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Renexin (cilostazol 100mg + gingko biloba extract 80 mg)</intervention_name>
    <description>Take Renexin 1T bid po medication for 8 weeks</description>
    <arm_group_label>Renexin</arm_group_label>
    <other_name>Renexin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Take placebo drug 1T bid po medication for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Renexin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recurrent vestibulopathy patient with symptoms more than 3 months of recurrent
             vertigo

          -  Visual analogue scale (VAS) score between 4 to 8

        Exclusion Criteria:

          -  Showing signs of central lesion in MRI or neurologic exams

          -  central nystagmus or loss of consciousness with vertigo

          -  cerebellar symptoms such as ataxia, dysarthria, gait disturbance

          -  Diagnosed as peripheral vertigo such as benign paroxysmal positional vertigo,
             Meniere's disease, migrainous vertigo in recent 3 months

          -  Bilateral vestibular dysfunction

          -  Vestibular neuronitis symptom appeared in recent 6 months

          -  Chronic liver disease (ALT&gt;100 or AST&gt;100) or chronic kidney disease (Creatinine &gt;
             3.0 mg)

          -  Blood Hemoglobin &lt; 10mg/dl (in male) or &lt; 8 mg/dl (in female)

          -  Contraindication for testing drug (ex. Pregnancy or breast feeding etc.)

          -  Taking antiepileptics such as phenobarbital, phenytoin, carbamazepine or rifampin in
             recent 2 weeks

          -  Taking cilostazol, gingko biloba for other disease

          -  Allergy/hypersensitivity to Renexin

          -  Severe drug toxicity when taking Renexin previously
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Woo Chung, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong Woo Chung</last_name>
      <phone>82-2-3010-3718</phone>
      <email>gfinder.jw@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>July 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Jong Woo Chung</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Renexin for Recurrent Vestibulopathy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vestibular Neuronitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
